Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ansornitinib
- Development stage
- Discontinued
- Lead developer
- Elicio Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ansornitinib (ANG-3070) is an orally bioavailable, small molecule multi-kinase inhibitor developed by Angion Biomedica for the treatment of fibrotic diseases. It primarily targets the platelet-derived growth factor receptor (PDGFR) and fibroblast growth factor receptor (FGFR) families, which are key mediators in the pathogenesis of fibrosis. The drug was evaluated in clinical trials for primary glomerular diseases, such as focal segmental glomerulosclerosis (FSGS), and idiopathic pulmonary fibrosis (IPF). However, in early 2023, Angion Biomedica suspended the clinical development of its pipeline, including ANG-3070, following a merger agreement with Elicio Therapeutics.
- Other names
- ansornitinibANG-3070ANG3070ANG 3070
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)FGFR1 (Fibroblast growth factor receptor 1)DDR1 (Discoidin domain receptor 1)DDR2 (Discoidin domain receptor tyrosine kinase 2)
Beyond the preview
Go deeper on ansornitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ansornitinib.